Cardiac Biomarkers Market: Global Industry Trends, Growth, Share, Size, Research Forecast By 2023

Global Cardiac Biomarkers Market Research Report, Trends, Growth, Share, Size and Forecast By 2024

Copyright © IMARC Service Pvt Ltd. All Rights Reserved

About IMARC Group

Report Description

IMARC is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations.

Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Report Description and Highlights

Report Description

Cardiac Biomarker Market Report By Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Ischemia Modified Albumin and Others) Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome and Others), Location of Testing, Region Cardiac biomarkers help as risk stratification for various cardiovascular diseases including myocardial infraction, congestive heart failure, and acute coronary syndrome.

Market Overview: According to the latest report by IMARC Group titled, “Cardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the market reached a value of US$ 6.9 Billion 2018. Looking forward, the global cardiac biomarkers market is expected to reach a value of US$ 11.6 Billion by 2024, exhibiting a CAGR of around 9% during 2019-2024. The major reason associated with this sharp rise in the demand for cardiac biomarkers is the increasing number of patients suffering from acute coronary syndrome across the globe. Other factors include continual technological advancements in the development of cardiovascular biomarkers, introduction of new product launches by the companies, rise in demand for point-of-care cardiac testing kits and highspecificity and -sensitivity of these biomarkers in detecting cardiovascular diseases, especially acute myocardial infarction. Apart from this, there has been a high degree of investments by numerous private and public organizations in the R&D activities to develop advanced technologies in the field of cardiac biomarkers.

Market Segmentation

Report Description

Cardiac Biomarkers Market Segmentation: Market Segmentation by Product Type o o o o o o

Troponins (T and I) Myocardial Muscle Creatine Kinase (CK-MB) Myoglobin Brain Natriuretic Peptide (BNPs) or NT-proBNP Ischemia Modified Albumin (IMA) Others

Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.

Market Segmentation by Location of Testing • •

Laboratory Testing Point of Care Testing

Request for a sample report: https://www.imarcgroup.com/request?type=report&id=1178&flag=B

Market Forecast

Sample Figure: Global: Cardiac Biomarkers Market Forecast: Sales Value (in Billion US$), 2019-2024

184.3

191.7

199.3

207.3

2019

2020

2021

2022

215.6

224.2

2023

2024

Market Segmentation

Report Description

Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.

Market Segmentation by Application • • • • •

Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome Atherosclerosis Others

Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.

Market Segmentation by Region • •

North America Europe

For more information, click here: https://www.imarcgroup.com/cardiac-biomarkers-market

Regional Segmentation

North America

Europ e

Asia- Pacific

Latin America

Middle East and Africa

Market Segmentation

Report Description • • •

Asia Pacific Latin America Middle East and Africa

Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for the majority of the global share.

Competitive Landscape: The competitive landscape of the market has also been examined with some of the key players.

• • • • • • • •

Abbott Laboratories Alere Inc Beckman Coulter Becton Dickinson And Co., Biomerieux Bio-Rad Laboratories, Randox Laboratories Roche Diagnostics Corporation

Market Segmentation

Report Description • •

Siemens Healthcare Thermo Fisher Scientific

In case you have a very specific customized or specific niche needs, we can work around the scope of work and assist you with the tailor made solution. The topics covered could be technology, markets, competition, pricing trends, P&L analysis, cost analysis, price bench marking or it could also be supplementing you with the weekly or fortnight reports.

Team Profile

Team Profile Our Team Comes From Some of the Top Universities Globally.

60% Engineering and Science

5% Others

35% Business Studies

Over 2000 Independent Consultants from different sectors.

Average Experience of 7+ Years

We are the trusted business partners to the

Partial List of Clients world's leading corporates, governments, and A partial List of our Clients institutions

We are the trusted business partners to the

Partial Listworld's of Clients leading corporates, governments, and

A partial List of our Clients

institutions

Report Description and Highlights

Report Description

© 2018 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

Contact Us

FOR MORE DETAILS Visit us at :

https://www.imarcgroup.com Stay With Us:

TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com